Compare MasTec Inc (MTZ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs TG Therapeutics Inc — how do they compare? MasTec Inc trades at $348.86 (market cap $26.60B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: MasTec Inc is far larger — about 3.2× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals.
| MTZ | TGTX | |
|---|---|---|
Market Cap | $26.60B | $8.26B |
Sector | Technology | Health |
52-Week High | $437.51 | $59.06 |
52-Week Low | $172.51 | $26.39 |
Enterprise Value | $29.34B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $336.61, up 2.13% today, amid strong analyst sentiment with 32 of 36 analysts rating it a Buy. The stock shows robust fundamentals with Q1 2026 EPS beating estimates by 40.6% and a record $20.3 billion backlog. Recent $1.65 billion acquisition of The Superior Group enhances data center infrastructure capabilities, positioning MTZ for AI-driven power demand growth. Technical indicators are bearish overall, with the stock trading near pivot point resistance at $338.
Outlook remains positive given earnings momentum and strategic expansion, though high P/E of 58.95 poses valuation risk. Upside to consensus price target of $497.45 offers 47.8% potential, but investors face execution risks from integration and debt-funded acquisitions. Revenue growth to $15.3 billion in 2026 supports bullish thesis if margins hold.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
